Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.2.411

Ki-67 is a Valuable Prognostic Factor in Gliomas: Evidence from a Systematic Review and Meta-analysis  

Chen, Wen-Jie (Department of Pathology, First Affiliated Hospital of Guangxi Medical University)
He, De-Shen (Department of Neurology, Seventh Affiliated Hospital of Guangxi Medical University, Wuzhou Worker Hospital)
Tang, Rui-Xue (Department of Pathology, First Affiliated Hospital of Guangxi Medical University)
Ren, Fang-Hui (Department of Pathology, First Affiliated Hospital of Guangxi Medical University)
Chen, Gang (Department of Pathology, First Affiliated Hospital of Guangxi Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.2, 2015 , pp. 411-420 More about this Journal
Abstract
Ki-67 has been widely used as an indicator of cell proliferation in gliomas. However, the role of Ki-67 as a prognostic marker is still undefined. Thus, we conducted a meta-analysis of the published literatures in order to clarify the impact of Ki-67 on survival in glioma cases. Eligible studies were identified in PubMed, EMBASE, ISI Web of Science, Cochrane Central Register of Controlled Trials, Science Direct and Wiley Online Library with the last search updated on August 31, 2014. The clinical characteristics, overall survival (OS) and progression-free survival (PFS) together with Ki-67 expression at different time points were extracted. A total of 51 studies, covering 4,307 patients, were included in the current meta-analysis. The results showed that overexpression of Ki-67 can predict poor OS (HR=1.66, 95%CI: 1.53-1.80; Z=11.87; p=0.000) and poor PFS (HR=1.67, 95%CI: 1.47-1.91; Z=7.67; p=0.000) in gliomas. Moreover, subgroup analyses also indicated that high level of Ki-67 expression was related to poor OS and PFS in glioma patients regardless of region, pathology type, cut-off value and statistical method. In conclusion, the current meta-analysis revealed that Ki-67 expression might be a predicative factor for poor prognosis of glioma patients, emphasizing its importance as a predictor.
Keywords
Ki-67; glioma; meta-analysis; immunohistochemistry; prognosis; survival;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Abd El Atti RM, Abou Gabal HH, Osman WM, et al (2013). Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors. Diagn Pathol, 8, 126.   DOI
2 Armstrong TS, Vera-Bolanos E, Bekele BN, et al (2010). Adult ependymal tumors: prognosis and the M.D. anderson cancer center experience. Neuro Oncol, 12, 862-70.   DOI
3 Bowers DC (2003). Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol, 21, 2968-73.   DOI
4 Bredel M, Piribauer M, Marosi C, et al (2002). High expression of DNA topoisomerase $II\alpha$ and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. European J Cancer, 38, 1343-7.   DOI
5 Chiang MDH, Ting ML-T, Hsu MDMHAC-Y, et al (2003). MIB-1 and DNA topoisomerase IIa could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol, 119, 715-22.   DOI
6 Coons SW, Johnson PC, Pearl DK (1997). The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery, 41, 878-85.   DOI
7 Dang YW, Zeng J, He RQ, et al (2014). Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev, 15, 4969-76.   DOI
8 Dehghani F, Schachenmayr W, Laun A, et al (1998). Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathologica, 95, 493-504.   DOI
9 Donato V, Papaleo A, Castrichino A, et al (2007). Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori, 93, 248.
10 Ellison DW, Steart PV, Bateman AC, et al (1995). Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry, 59, 413-9.   DOI
11 Fakhrjou A, Dastranj-Tabrizi A, Ghojazadeh M, et al (2013). Diagnostic value of protein Ki67 (MIB-1) in atypical Pap smears of postmenopausal women. Asian Pac J Cancer Prev, 14, 4815-8.   DOI   ScienceOn
12 Figarella-Branger D, Civatte M, Bouvier-Labit C, et al (2000). Prognostic factors in intracranial ependymomas in children. J Neurosurg, 93, 605-13.   DOI
13 Habberstad AH, Gulati S, Torp SH (2011). Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIa in human anaplastic astrocytomas-an immunohistochemical study. Diagn Pathol, 6, 43.   DOI
14 Haroon S, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8.   DOI
15 Heegaard S, Sommer HM, Broholm H, et al (1995). Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer, 76, 1809-13.   DOI
16 Hernandez-Pedro NY, Rangel-Lopez E, Magana-Maldonado R, et al (2013). Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int, 2013, 351031.
17 Higgins J, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21, 1539-58.   DOI
18 Ho DM-T, Hsu C-Y, Wong T-T, et al (2001). A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neuro-Oncol, 54, 77-85.   DOI
19 Huang S, Chen G (2014). Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. Scientific World J, 2014, 605236.
20 Hu X, Miao W, Zou Y, et al (2013). Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol Letters, 6, 130-4.
21 Huang T, Jin X, He L, et al (2013). Role of podocalyxin in astrocytoma: clinicopathological and evidence. Oncol Lett, 6, 1390-6.
22 Jaros E, Perry R, Adam L, et al (1992). Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer, 66, 373.   DOI
23 Kanamori M, Kumabe T, Sonoda Y, et al (2008). Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neuro-Oncol, 93, 219-28.
24 Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, et al (2006). Characterization of glioblastomas in young adults. Brain Pathology, 16, 273-86.   DOI
25 Kohler BA, Ward E, McCarthy BJ, et al (2011). Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst, 103, 714-36   DOI
26 Kouri FM, Jensen SA, Stegh AH (2012). The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. Scientific World J, 2012, 838916.
27 Kros JM, Hop WC, Godschalk JJ, et al (1996). Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer, 78, 1107-13.   DOI
28 Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intl Med, 127, 820-6.   DOI
29 Kuo LT, Kuo KT, Lee MJ, et al (2009). Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer, 124, 2872-9.   DOI
30 Laks DR, Masterman-Smith M, Visnyei K, et al (2009). Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells, 27, 980-7.   DOI
31 Li S-W, Qiu X-G, Chen B-S, et al (2009). Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J, 122, 1245-9.
32 Liu Y, Tang K, Yan W, et al (2013). Identifying Ki-67 specific miRNA-mRNA interactions in malignant astrocytomas. Neuroscience Letters, 546, 36-41.   DOI
33 Margraf LR, Gargan L, Butt Y, et al (2011). Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas-an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol, 13, 767-74.   DOI
34 McKeever PE, Strawderman MS, Yamini B, et al (1998). MIB- 1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol, 57, 931-6.   DOI
35 Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al (1994). Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery, 34, 674-9.   DOI
36 Nabika S, Kiya K, Satoh H, et al (2010). Prognostic significance of expression patterns of EGFR family, p21 and p27 in high-grade astrocytoma. Hiroshima J Med Sci, 59, 65-70.
37 Nazarenko I, Hede SM, He X, et al (2012). PDGF and PDGF receptors in glioma. Ups J Med Sci, 117, 99-112.   DOI
38 Park KJ, Kang SH, Park DH, et al (2012). Usefulness of thallium-201 SPECT for prediction of early progression in low-grade astrocytomas diagnosed by stereotactic biopsy. Clin Neurol Neurosurg, 114, 223-9.   DOI
39 Neder L, Colli B, Machado H, et al (2003). MIB-1 labeling index in astrocytic tumors-a clinicopathologic study. Clin Neuropathol, 23, 262-70.   DOI
40 Okita Y, Narita Y, Miyakita Y, et al (2012). Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol, 29, 192-200.   DOI
41 Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.   DOI
42 Phi JH, Wang KC, Park SH, et al (2012). Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. J Neurooncol, 106, 619-26.   DOI
43 Pollack IF, Campbell JW, Hamilton RL, et al (1997). Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer, 79, 849-56.   DOI
44 Pollack IF, Hamilton RL, Burnham J, et al (2002). Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery, 50, 1238-45.
45 Preusser M, Hoeftberger R, Woehrer A, et al (2012). Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European organization for research and treatment of cancer brain tumor group. Histopathology, 60, 885-94.   DOI
46 Preusser M, Wolfsberger S, Czech T, et al (2005). Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol, 124, 543-9.   DOI
47 Rodriguez-Pereira C, Suarez-Penaranda J, Vazquez-Salvado M, et al (2000). Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study. J Neurosurg Sci, 44, 203-9; discussion 9-10.
48 Qiang J, Wei Z, Xiao-Guang Q, et al (2011). Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. Chinese Med J Beijing, 124, 2584.
49 Reavey-Cantwell JF, Haroun RI, Zahurak M, et al (2001). The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neuro-Oncol, 55, 195-204.   DOI
50 Ritter AM, Hess KR, McLendon RE, et al (1998). Ependymomas: MIB-1 proliferation index and survival. J Neurooncol, 40, 51-7.   DOI
51 Shen C, Yang L, Yuan X (2011). Endothelin B receptor expression in human astrocytoma: association with clinicopathological variables and survival outcomes. Int J Neurosci, 121, 626-31.   DOI
52 Tadbir AA, Pardis S, Ashkavandi ZJ, et al (2012). Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev, 13, 5155-9.   DOI   ScienceOn
53 Tian B, Zhang Y, Zhang J (2014). Periostin is a new potential prognostic biomarker for glioma. Tumour Biol, 35, 5877-83.   DOI
54 Torp S, Helseth E, Dalen A, et al (1992). Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochirurgica, 117, 182-6.   DOI
55 Tove L-L, Hansson HA, Stein S, et al (2012). Prognostic value of histological features in diffuse astrocytomas WHO grade II. Interl J Clin Experimental Pathol, 5, 152.
56 Wessels PH, Hopman AH, Kubat B, et al (2003). Proliferation and aneusomy predict survival of young patients with astrocytoma grade II. Br J Cancer, 89, 128-34.   DOI
57 Uematsu M, Ohsawa I, Aokage T, et al (2005). Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol, 72, 231-8.   DOI
58 Watanabe Y, Yamasaki F, Kajiwara Y, et al (2010). Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol, 100, 449-57.   DOI
59 Wen PY, Kesari S (2008). Malignant gliomas in adults. New England J Med, 359, 492-507.   DOI
60 Westermark B (2012). Glioblastoma-a moving target. Ups J Med Sci, 117, 251-6.   DOI
61 Yang P, Wang Y, Peng X, et al (2013). Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol, 113, 259-66.   DOI
62 Yoshida Y, Nakada M, Harada T, et al (2010). The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol, 98, 41-7.   DOI
63 Yue Q, Zhang X, Ye HX, et al (2014). The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol, 116, 251-9.   DOI
64 Zamecnik J, Snuderl M, Eckschlager T, et al (2003). Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Modern Pathol, 16, 980-91.   DOI
65 Zhong D, Li X, Zhang G (2001). Multivariate analysis of the parameters related to prognosis of astrocytoma. Zhonghua Bing Li Xue Za Zhi Chinese J Pathol, 30, 345-9.
66 Zawrocki A, Izycka-Swieszewska E, Papierz W, et al (2011). Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review. Folia Neuropathol, 49, 94-102.
67 Zhao S, Wu J, Wang C, et al (2013). Intraoperative fluorescenceguided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS One, 8, e63682.   DOI